Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese

Table 4

Multivariate analysis of rivaroxaban and CRNMB in obese patients.

Variables	Odds ratio estimate	95% Wald confidence interval
BMI ≥30 versus <30	1.15	0.34–3.89
Age	1.052	1.00–1.11
Male	0.59	0.19–1.84
Caucasian versus African American	0.67	0.22–2.03
Dose of rivaroxaban	0.98	0.82–1.17
Interacting medications	6.73	1.70–26.74
Aspirin	0.63	0.18–2.21
Plavix	9.21	0.25–341.92
History of prior bleeding	0.27	0.05–1.48

This table presents the multivariate logistical regression model for rivaroxaban and odds ratios for outcome of CRNMB in obese patients compared to normal weight controls in the NVAF cohort.